Urogen Pharma Ltd
(URGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 91,386 | 93,986 | 105,109 | 173,063 | 125,989 |
| Marketable Securities | 36,994 | 64,050 | 91,857 | 64,698 | 124,659 |
| Receivables | 19,703 | 19,649 | 19,638 | 20,302 | 22,802 |
| Inventories | 8,341 | 7,128 | 7,590 | 9,227 | 7,594 |
| TOTAL | $168,546 | $196,868 | $237,177 | $276,135 | $295,097 |
| Non-Current Assets | |||||
| PPE Net | 695 | 688 | 627 | 655 | 608 |
| Investments And Advances | 380 | 4,632 | 4,514 | 5,022 | 4,641 |
| Other Non-Current Assets | 15,425 | 6,529 | 5,300 | 3,899 | 1,597 |
| TOTAL | $16,500 | $11,849 | $10,441 | $9,576 | $6,846 |
| Total Assets | $185,046 | $208,717 | $247,618 | $285,711 | $301,943 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 26,173 | 30,962 | 30,322 | 27,431 | 19,685 |
| Accrued Expenses | 11,114 | 11,646 | 6,967 | 10,570 | 9,029 |
| Other current liabilities | 4,957 | 4,940 | 4,711 | 7,948 | 4,073 |
| TOTAL | $42,244 | $47,548 | $42,000 | $45,949 | $32,787 |
| Non-Current Liabilities | |||||
| Long Term Debt | 122,111 | 122,508 | 122,108 | 121,734 | 121,709 |
| Other Non-Current Liabilities | 136,099 | 132,037 | 129,968 | 126,831 | 121,932 |
| TOTAL | $258,210 | $254,545 | $252,076 | $248,565 | $243,641 |
| Total Liabilities | $300,454 | $302,093 | $294,076 | $294,514 | $276,428 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 46,809 | 46,264 | 46,107 | 46,094 | 42,199 |
| Common Shares | 128 | 126 | 126 | 115 | 115 |
| Retained earnings | -933,352 | -900,005 | -850,065 | -806,222 | -768,710 |
| Other shareholders' equity | 23 | 6 | 14 | 56 | 236 |
| TOTAL | $-115,408 | $-93,376 | $-46,458 | $-8,803 | $25,515 |
| Total Liabilities And Equity | $185,046 | $208,717 | $247,618 | $285,711 | $301,943 |